ArticleScientific reports2026
Detection of reduced susceptibility of Anopheles Gambiae s.l. to pirimiphos-methyl in Benin.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insecticide resistance in Anopheles gambiae s.l. threatens malaria vector control strategies in sub-Saharan Africa. Organophosphates such as pirimiphos-methyl have been deployed in Benin through Indoor Residual Spraying (IRS) since 2013 as alternatives to pyrethroids. However, no published evidence had documented resistance to this compound. This study provides the first confirmation of reduced susceptibility to pirimiphos-methyl in Benin and investigates potential resistance mechanisms. The study was conducted from January 2022 to December 2024. Larvae of An. gambiae s.l. were collected from 20 districts along a north-south transect of Benin and reared to adults under insectary conditions. Susceptibility tests were performed according to WHO protocols using 0.25% pirimiphos-methyl-impregnated papers, and 24-h mortality was recorded. Molecular assays were conducted for species identification and detection of the Ace-1R (G119S) mutation. A total of 1,744 females were tested. Full susceptibility was observed in eight districts. Suspected and confirmed resistance was detected in eight and four districts, respectively, including key IRS-treated areas. Molecular analysis identified An. coluzzii (47.7%), An. gambiae s.s. (47.9%), and An. arabiensis (4.4%). The Ace-1R mutation occurred at low frequencies (< 5%), suggesting a limited role of target-site resistance. This study provides the first evidence of pirimiphos-methyl resistance in An. gambiae s.l. populations in Benin. The findings underline the need for: (i) strengthened and geographically expanded resistance surveillance, (ii) rotation or replacement of pirimiphos-methyl with new chemistries such as clothianidin or chlorfenapyr, and (iii) reinforcement of integrated resistance management strategies to preserve the effectiveness of IRS and other vector control interventions. These recommendations are essential for supporting national malaria control programs in evidence-based decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.